Related Experiment Video

Updated: Jun 19, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

THE MODIFYING EFFECTS OF CERTAIN SUBSTANCES OF BACTERIAL ORIGIN ON THE COURSE OF INFECTION WITH PNEUMONIA VIRUS OF

F L Horsfall1, M McCarty

  • 1Hospital of The Rockefeller Institute for Medical Research.

The Journal of Experimental Medicine
|October 30, 2009
PubMed

Insights

Certain polysaccharide preparations, from bacteria or other sources, reduce pneumonia virus of mice (PVM) infection severity. These compounds also inhibit PVM replication in mouse lungs, suggesting a polysaccharide-mediated antiviral effect.

Area of Science:

  • Virology
  • Immunology
  • Biochemistry

Background:

  • Pneumonia virus of mice (PVM) causes respiratory infections.
  • Understanding host-pathogen interactions is crucial for developing antiviral strategies.

Purpose of the Study:

  • To investigate the antiviral effects of polysaccharide preparations against PVM infection.
  • To determine if these polysaccharides can inhibit PVM replication in vivo.

Main Methods:

  • Administration of polysaccharide preparations to mice infected with PVM.
  • Assessment of infection severity and viral load in mouse lungs.

Main Results:

  • Polysaccharide preparations significantly lessened the severity of PVM infection.
  • Inhibition of PVM multiplication in the lungs of treated mice was observed.
  • The data suggests a potential polysaccharide-mediated modification of the virus.

Conclusions:

  • Certain bacterial and non-bacterial polysaccharides exhibit significant antiviral activity against PVM.
  • These findings highlight the potential of polysaccharides as therapeutic agents for PVM infections.
Keywords:
PNEUMONIA/virusPROTEINASESERUM/immuneTOXIN

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Regulation of Bacterial Virulence01:28

Regulation of Bacterial Virulence

Pathogenic bacteria employ a range of regulatory mechanisms to modulate the expression of virulence genes in response to environmental and host-derived signals. These mechanisms ensure that virulence factors are expressed only under favorable conditions, thereby optimizing infection and survival strategies.Mechanisms of Virulence RegulationKey regulatory strategies include:Two-Component Systems: These consist of a membrane-bound sensor kinase and a cytoplasmic response regulator. Environmental...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: